Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Peking Union Medical College Hospital
The study started on July 2021 and will last 1.5 years. Primary APS patients with three positive aPL and extra-criteria manifestations with be enrolled. This is a single-arm pilot study. Telitacicept 160mg once a week for 24 weeks will be added on traditional antithrombotic and immunosuppressive treatment. Patients will be followed on week 12 and week 24. The primary endpoint is new thrombotic event. The secondary endpoints are improvement of extra-criteria manifestations, and titer change of aPL.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
meet 2006 Sapporo classification criteria of APS;
diagnosis of primary APS, exclude other etiologies of thrombosis;
with three aPL medium-to-high titer positivity, namely lupus anticoagulant, anti cardiolipin antibody, and anti-β2 glycoprotein antibody;
with at least one extra-criteria manifestations of APS, including thrombocytopenia, hemolytic anemia, aPL nephropathy, valve heart disease and neurological manifestations.
You may not be if
overlap with other connective tissue diseases, such as systemic lupus erythematosus;